Maria Aranzazu B. R.
- Country
- Spain
- Department
- Servicio de Hematologia
Research Overview
- Safety Evaluation of CC-93269 in Patients with Relapsed and Refractory Multiple Myeloma
- Phase 1 Dose-Escalation Study of CC-92328 in Patients with Relapsed/Refractory Multiple Myeloma
- A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematopoietic cell transplantation complications
Data & Insights
Has run more than one trial at 136 of 234 partner sites.
Specializations
Hematologic Malignancies
This investigator specializes in treating multiple myeloma and plasma cell leukemia, with particular focus on novel therapeutic approaches for patients with relapsed or refractory disease.
- Primary plasma cell leukemia management
- CART cell therapy applications
- Multiple myeloma post-transplant care
Their work includes evaluating innovative cellular therapies and investigating treatment options for newly diagnosed conditions.
Transplant Complications
The investigator focuses on managing complications following allogeneic stem cell transplantation, particularly in the treatment and prevention of graft-versus-host disease.
- Acute and chronic GVHD treatment
- Novel therapeutic combinations
- Steroid-refractory GVHD management
Their research encompasses both acute and chronic manifestations of GVHD, with emphasis on gastrointestinal involvement.
Infection Prevention
The investigator studies preventive strategies for post-transplant infections, particularly focusing on cytomegalovirus infections in transplant recipients and innovative microbiome-based approaches.
- CMV prophylaxis protocols
- Microbiome therapeutics
- Post-transplant infection management
Their work includes evaluation of novel prophylactic treatments and monitoring strategies for immunocompromised patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.